2011, Number 2
Metabolic alteration in children infected with Human Immunodeficiency Virus secondary to a Highly Active Antiretroviral Therapy
PDF size: 496.37 Kb.
ABSTRACTThe implementation of the Highly Active Antiretroviral Therapy (HAART) has decreased the progression of the disease increasing the life expectancy in HIV pediatric patients, but at the same time, it raised the morbidity associated with this therapy. The complications involved are dyslipidemia, insulin resistance, osteopenia among others. Particularly, it has been proven that the protease inhibitors (PI) are significant risk factors for the development of hypercholesterolemia. In prospective cohort studies, it has been found that high viral load is considered a protector factor for the metabolic alterations on patients under a HAART, showing an inadequate adherence to the medical treatment. Therefore, despite the success in the viral management in children with HAART, the consequences of this therapy remain as a serious health problem for the long-term metabolic disorders.
Taylor P. , Worrell C., Steinberg S. M., Hazra R., Jankelevich S., Wood L. V. et al. Natural history of lipid abnormalities and fat redistribution among Human Immunodeficiency Virus-infected children receiving long-term, protease inhibitor-containing highly active antiretroviral therapy regiments. Pediatrics; 2004, 114:235-42.